Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Objective: Investigate the direct correlation of CYP3A5 genotype with tacrolimus trough
levels and clinical outcomes. The primary endpoint of this study is to evaluate the
proportion of patients reaching target levels (8-10 ng/mL) on Day 3 and Day 7 after kidney
transplantation.